Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons

Pharmacological Reviews

Volumn 55, Issue 3, 2003, Pages 509-550

  Agnati, Luigi F ^b   Ferré, Sergi ^b   Lluis, Carme ^b   Franco, Rafael ^b   Fuxe, Kjell ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ANGIOTENSIN RECEPTOR; BRADYKININ B2 RECEPTOR; CALCITONIN RECEPTOR; DELTA OPIATE RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HEPTAHELICAL RECEPTOR; ION CHANNEL; KAPPA OPIATE RECEPTOR; MEMBRANE PROTEIN; MEMBRANE RECEPTOR; METABOTROPIC RECEPTOR; MU OPIATE RECEPTOR; OLIGOMER; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVITY MODIFYING PROTEIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SOMATOSTATIN 1 RECEPTOR; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL COMMUNICATION; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DRUG DEPENDENCE; GLOBUS PALLIDUS; LEARNING; MEMORY; MOLECULAR MECHANICS; NIGRONEOSTRIATAL SYSTEM; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SCHIZOPHRENIA; STRIATOPALLIDAL NEURON;

ANIMALS; BRAIN; CELL MEMBRANE; DIMERIZATION; DRUG DESIGN; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; NEURONS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GABA; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS;

EID: 0042467972     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.55.3.2     Document Type: Review

References (426)

1. AbdAlla S, Lother H, el Massiery A, and Quitterer U (2001) Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7:1003-1009.
2. 1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature (Lond) 407:94-98.
3. Abel T and Kandel E (1998) Positive and negative regulatory mechanims that mediate long-term memory storage. Brain Res Rev 26:360-378.
4. Adams MR, Brandon EP, Chartoff EH, Idzerda RL, Dorsa DM, and McKnight GS (1997) Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. Proc Natl Acad Sci USA 94:12157-12161.
5. Agnati L, Fuxe K, Benfenati F, Mutt V, and Hökfelt T (1983c) Differential modulation by CCK-8 and CCK-4 of [3H]spiperone binding sites linked to dopamine and 5-HT receptors in the brain of the rat. Neurosci Lett 35:179-183.
6. Agnati LF, Benfenati F, Ferri M, Morpurgo A, Apolloni B, and Fuxe K (2002) Molecular basis of learning and memory: modeling based on receptor mosaics, in From Synapses to Rules: Discovering Symbolic Rules From Neural Processed Data (Apolloni B and Kurfess F eds), pp 165-195, Kluwer Academic/Plenum Press Publisher, New York.
7. Agnati LF, Benfenati F, Solfrini V, Biagini G, Fuxe K, Guidolin D, Carani C, and Zini I (1993) Intramembrane receptor/receptor interactions: integration of signal transduction pathways in the nervous system. Neurochem Int 22:213-222.
8. 3H] N-propylnorapomorphine binding sites. Acta Physiol Scand 118:79-81.
9. Agnati LF, Franzén O, Ferré S, Franco R, and Fuxe K (2003) Possible role of intramembrane receptor/receptor interactions in memor and learning via formation of long-lived heteromeric complexes: focus on motor learning in basal ganglia. J Neural Transm 65:195-222.
10. Agnati LF and Fuxe K (2000) Volume transmission as a key feature of information handling in the central nervous system. Possible new interpretative value of the Turing's B-type machine. Prog Brain Res 125:3-19.
11. 3H] N-propylnorapomorphine binding sites. Acta Physiol Scand 119:459-461.
12. 2-adrenergic binding sites in membranes of the medulla obolngata of the rat. Acta Physiol Scand 118:293-295.
13. Agnati LF, Fuxe K, Benfenati F, Battistini N, Zini I, Camurri M, and Hökfelt T (1984) Postsynaptic effects of neuropeptide comodulators at central monoamine synapses, in Neurology and Neurobiology (Usdin E, Carlsson A, Dahlström A, and Engel J eds) pp 191-198, Alan R. Liss, New York.
14. 3H] 5-HT binding sites. Acta Physiol Scand 117:299-301.
15. Agnati LF, Fuxe K, Giardiano L, Calza L, Zoli M, Battistini N, Benfenati F, Vanderhaeghen JJ, Guidolin D, Ruggeri M, et al. (1985) Evidence for cholecystokinin-dopamine receptor interactions in the central nervous system of the adult and old rat. Ann NY Acad Sci 448:315-333.
16. Agnati LF, Fuxe K, Merlo-Pich E, Zoli M, Zini I, Benfenati F, Härfstrand A, and Goldstein M (1987) Aspects on the integrative capabilities of the central nervous system: evidence for "volume transmission" and its possible relevance for receptor/receptor interactions in Receptor/receptor Interactions (Fuxe, K and Agnati LF eds) pp 236-249, Macmillan, London.
17. Agnati LF, Fuxe K, Zini I, Lenzi P, and Hökfelt T (1980) Aspects on receptor regulation and isoreceptor identification. Med Biol (Helsinki), 58:182-187.
18. Agnati LF, Fuxe K, Zoli M, Merlo Pich E, Benfenati F, Zini I, and Goldstein M (1986) Aspects on the information handling by the central nervous system: focus on cotransmission in the aged rat brain. Prog Brain Res 68:291-301.
19. Agnati LF, Fuxe K, Zoli M, Rondanini C, and Ogren SO (1982) New vistas on synaptic pasticity: mosaic hypothesis on the engram. Med Biol 60:183-190.
20. Agnati LF, Zoli M, Merlo Pich E, Benfenati F, and Fuxe K (1990) Aspects of neural plasticity in the central nervous system. VII. Theoretical aspects of brain communication and computation. Neurochem Int 16:479-500.
21. Agnati LF, Zoli M, Merlo-Pich E, Ruggeri M, and Fuxe K (1988) The emerging complexity of the brain. Limits of brain-computr analogy, in Traffic Engineering for ISDN Design and Planning (Bonatti M and Decina M eds) pp 209-230, Elsevier Science B.V., Amsterdam.
22. Aguirre JA, Fuxe K, Hedlund P, Narváez JA, Cintra A, Rosén L, and Agnati LF (1991) Neuropeptide Y/angiotensin II interactions in central cardiovascular regulation of the rat. Brain Res 566:61-69.
23. Alexander GE and Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13:266-27.
24. Alger BE and Nicoll RA (1979) GABA mediated biphasic inhibitory responses in hippocampus. Nature (Lond) 281:315-317.
25. Angers S, Salahpour A, Joly E, Hilaret S, Chelsky D, Dennis M, and Bouvier M (2000) Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET) Proc Natl Acad Sci USA 97:3684-3689.
26. Aoyama S, Kase H, and Borrelli E (2000) Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 20:5848-5852.
27. Avissar S, Amitai G, and Sokolovsky M (1983) Oligomeric structure of muscarinic receptors is shown by photoaffinity labeling: subunit assembly may explain high- and low-affinity agonist states. Proc Natl Acad Sci USA 80:156-159.
28. Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, and Selby PJ (2000) Proteomics: new perspectives, new biomedical opportunities. Lancet 356:1749-1756.
29. Barraco RA, Martens KA, Parizon M, and Normile HJ (1993) Adenosine A2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 31:397-404.
30. Bergson C, Mazljak L, Sniley JF, Pappy M, Levenson R, and Goldman-Rakic PS (1995) Regional cellular and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 15:7821-7836.
31. Berke JD and Hyman SE (2000) Addiction, dopamine and the molecular mechanisms of memory. Neuron 25:515-532.
32. Bettler B, Kaupmann K, and Bowery NG (1998) GABAB receptors: drugs meet clones. Curr Opin Neurobiol 8:345-350.
33. Bockaert J and Pin JP (1999) Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO (Eur Mol Biol Organ) J 18:1723-1729.
34. Boegman RJ and Vincent SR (19965 Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse 22:70-77.
35. Bohen SP, Kralli A, and Yamamoto KR (1995) Hold'em and fold'em: chaperones and signal transduction. Science (Wash DC) 268:1303-1304.
36. Bond RA and Bouvier M (1998) Receptor-Based Drug Design (Leff P ed) pp 363-377, Marcel Dekker, Inc., New York.
37. Borsook D and Hyman SE (1995) Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Am J Physiol 269: E393-E408.
38. Bouvier M (2001) Oligomerization of G-protein-coupled transmitter receptors. Nat Neurosci 2:274-286.
39. Breysse N, Baunez C, Spooren W, Gasparini F, and Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits n a rat model of Parkinsonism. J Neurosci 22:5669-5678.
40. Caplan AJ, Langley E, Wilson EM, and Vidal J (1995) Hormone-dependent trans-activation by the human androgen receptor is regulated by a dnaJ protein. J Biol Chem 270:5251-5257.
41. Carlezon WA Jr and Wise RA (1996) Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 16:3112-3122.
42. Carlsson M and Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia. Implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
43. Cartmell J, Goepfert F, Knoflach F, Pink JR, Bleuel Z, Richards JG, Schaffhauser H, Kemp JA, Wichmann J, and Mutel V (1998) Effect of metabotropic glutamate receptor activation on receptor-mediated cyclic AMP responses in primary cultures of rat striatal neurones. Brain Res 791:191-199.
44. 1 adenosine receptor from pig brain. Characterization and evidence of the role of the cell membrane on the coexistence of the high and low-affinity states. J Neurosci Res 26:461-473.
45. Casadó V, Mallol J, Lluís C, Franco R, and Canela EI (1991) Adenosine receptors in myelin fractions and subfractions: the effect of the agonist (R)-phenylisopropyladenosine on myelin membrane microviscosity J Neurochem 57:1623-1629.
46. Casas M, Ferre S, Guix T, and Jane F (1988) Theophylline reverses haloperidol. induced catalepsy in the rat. Possible relevance to the pharmacological treatment of psychosis. Biol Psychiatry 24:642-648.
47. Changeux J and Edelstein SJ (2001) Allosteric mechanisms in normal and pathological nicotinic acetylcholine receptors. Curr Opin Neurobiol 11:369-377.
48. Changeux J-P, Thiéry J-P, Tung T, and Kittel C (1967) On the cooperativity of biological membranes. PNAS 57:335-341.
49. Chase TN and Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23:S86-S91.
50. Chen JF, Beilstein M, Xu YH, Turner TJ, Moratalla R, Standaert DG, Aloyo VJ, Fink JS, and Schwarzschild MA (2000) Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 97:195-204.
51. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ, et al. (2001) The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 98:1970-1975.
52. Chen WJ, Armour S, Way J, Chen G, Watson C, Irveng P, Cobb J, Kadwell L, Beaumont K, Rimele T, et al. (1997) Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors. Mol Pharmacol 52:1164-1175.
53. Chiacchio S, Scarselli M, Armogida M, and Maggio R (2000) Pharmacological evidence of muscarinic receptor heterodimerization. Pharm Acta Helv 74:315-326.
54. Chneiweiss J, Glowinski J, and Premont J (1985) Modulation by monoamines of somatostatin-sensitive adenylate cyclase on neuronal and glial cells from the mouse brain in primary cultures. Neurochemistry 44:1825.
55. Cho K and Bashir Z (2002) Cooperation between mglu receptors: a depressing mechanism? Trends Neurosci 25:405-411.
56. Choe ES and Wang JQ (2001) Group I metabotropic glutamate receptors control phosphorylation of CREB, Elk-1 and ERK via a CaMKII-dependent pathway in rat striatum. Neurosci Lett 313:129-132.
57. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, and Sexton PM (1999) Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56:235-242.
58. Ciruela F, Casadó V, Mallol J, Canela EI, Lluis C, and Franco R (1995) Immunological identification of A1 adenosine receptors in brain cortex. J Neurosci Res 42:818-828.
59. Ciruela F, Escriche M, Burgueno J, Angulo E, Casado V, Soloviev MM, Canela EI, Mallol J, Chan WY, Lluis C, et al. (2001a) Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes. J Biol Chem 276:18345-18351.
60. Ciruela F, Escriche M, Soloviev MM, Canela EI, Burgeño J, Mallol J, Chan WY, Lluís C, McIlhinney RAJ, and Franco R (2001b) Adenosine-glutamate receptor/receptor interactions in the central nervous system. Drug Dev Res 52:316-322.
61. Ciruela F, Saura C, Canela El, Mallol J, Lluis C, and Franco R (1996) Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 380:219-223.
62. Ciruela F, Soloviev MM, Chan WY, and McChinney RA (2000) Homer-1c/ Ves1-1L modulates the cell surface targeting of metabotropic glutamate receptor type 1α: evidence for an anchoring function. Mol Cell Neurosci 15:36-50.
63. Cochran A (2000) Antagonists of protein-protein interactions. Chem Biol 7:R85-R94.
64. Cochran A (2001) Protein-protein interfaces: mimics and inhibitors. Curr Opin Chem Biol 5:654-659.
65. Cohn ML and Cohn M (1975) "Barrel rotation" induced by somatostatin in the nonlesioned rat. Brain Res 96:138.
66. Conn PM, Rogers DC, Stewart JM, Niedel J, and Sheffield T (1982) Conversion of a gonadotrohin-releasing hormone antagonist to an agonist. Nature (Lond) 296:653-655.
67. Cordeaux Y, Briddon SJ, Megson AE, McDonnell J, Dickenson JM, and Hill SJ (2000) Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A1 receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. Mol Pharmacol 58:1057-1084.
68. d'Alcantara P, Ledent C, Swillens S, and Schiffmann SN (2001) Inactivation of adenosine A(2A) receptor impairs long term potentiation in the accumbens nucleus without altering basal. Neuroscience 107:455-464.
69. Dale LB, Babwah AV, and Ferguson SSG (2002) Mechanisms of metabotropic glutamate receptor desensitization: role in the patterning of effector enzyme activation. Neurochem Int 41:319-326.
70. 2 receptors in stably cotransfected fibroblast cells. Eur J Pharmacol 316:325-331.
71. 2L receptor cDNAs. Mol Brain Res 36:292-299.
72. Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, Arckens L, Zoli M, and Schiffmann SN (2001) Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J Neurochem 78:183-198.
73. Delle Donne KT, Sesack SR, and Pickel VM (1997) Ultrastructural immunocyto-chemical localization of the dopamine D2 receptor within GABAergic neurons of the rat striatum. Brain Res 746:239-255.
74. Deutch AY, Lee MC, and Iadarola MJ (1992) Regional specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:322-341.
75. Diaz-Cabiale Z, Fuxe K, Narváez JA, Finetti S, Antonelli T, Tanganelli S, and Ferraro L (2002a) Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum. Counteraction by a NTR1-like receptor antagonist. Neuroreport 13:763-766.
76. Díaz-Cabiale Z, Hurd Y, Guidolin D, Finnman UB, Zoli M, Agnati LF, Vanderhaeghen JJ, Fuxe K, and Ferré S (2001) Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. Neuroreport 12:1831-1834.
77. Diaz-Cabiale Z, Narváez JA, Finnman U-B, Bellido I, Ogren SO, and Fuxe K (2000a) Galanin(1-16) modulates 5-HT1A receptors in the ventral limbic cortex of the rat. Neuroreport 11:515-519.
78. Diaz-Cabiale Z, Narváez JA, Garrido R, Petersson M, Uvnäs-Moberg K, and Fuxe K (2000b) Antagonistic ocytocin/a2-adrenoreceptor interactions in the nucleus tractus solitarii: relevance for central cardiovascular contol. J Neuroendocrinol 12:1167-1173.
79. Diaz-Cabiale Z, Narváez JA, Petersson M, Uvnäs-Moberg K, and Fuxe K (2000c) Oxytocin/alpha2-adrenoceptor interactions in feeding responses. Neuroendocrinology 71:209-218.
80. Diaz-Cabiale Z, Narváez JA, Yanaihara N, González-Barón S, and Fuxe K (2000e) Galanin/alpha2-receptor interactions in central cardiovascular control. Neuropharmacology 39:1377-1385.
81. Diaz-Cabiale Z, Petersson M, Narváez JA, Uvnäs-Moberg K, and Fuxe K (2000d) Systemic oxytocin treatment modulates a2-adrenoreceptors in telencephalic and diencephalic regions of the rat. Brain Res 887:421-425.
82. Díaz-Cabiale Z, Vivo M, Del Arco A, O'Connor WT, Harte MK, Müller CE, Martínez E, Fuxe K, Popoli P and Ferré S (2002b) Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway. Interactions with adenosine A2A and dopamine D2 receptors. Neurosci Lett 324:154-158.
83. Dixon AK, Widdowson L, and Richardson PJ (1997) Desensitisation of the adenosine A1 receptor by the A2A receptor in the rat striatum. J Neurochem 69:315-321.
84. Domingues H, Cregut D, Sebald W, Oschkiat H, and Serrano L (1999) Rational design of a GCN4-derived mimetic of interleukin-4. Nat Struct Biol 6:652-656.
85. Duke TA and Bray D (1999) Heightened sensitivity of a lattice of membrane receptors. Proc Natl Acad Sci USA 96:10104-10108.
86. Edwards AS and Scott JD (2000) A-kinase anchoring proteins: protein kinase A and beyond. Curr Opin Cell Biol 12:217-221.
87. Egan SE and Weinberg RA (1993) The pathway to signal achievement. Nature (Lond) 365:781-783.
88. Evers BM, Wang X, Zhou Z, Townsend CM Jr, McNeil GP, and Dobner PR (1995) Characterization of promoter elements required for cell-specific expression of the neurotensin/neuromedin N gene in a human endocrine cell line. Mol Cell Biol 15:3870-3881.
89. Fenu S, Cauli O, and Morelli M (2000) Cross-sensitization between the motor activating effects of bromocriptine and caffeine: role of adenosine A2A receptors. Behav Brain Res 114:97-105.
90. Fenu S and Morelli M (1998) Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors. Eur J Neurosci 10:1878-1884.
91. Fenu S, Pinna A, Ongini E, and Morelli M (1997) Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143-147.
92. Ferraguti F, Baldani-Guerra B, Corsi M, Nakanishi S, and Corti C (1999) Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur J Neurosci 11:2073-2082.
93. Ferraro L, O'Connor WT, Antonelli T, Fuxe K, and Tanganelli S (1997) Differential effects of intrastriatal neurotensin(1-13) and neurotensin(8-13) on striatal dopamine and pallidal GABA release. A dual-probe microdialysis study in the awake rat. Eur J Neurosci 9:1838-1846.
94. Ferré S (1997) Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 133:107-120.
95. Ferré S, Fredholm BB, Morelli M, Popoli P, and Fuxe K (1997) Adenosine-dopamine receptor/receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482-487.
96. Ferré S and Fuxe K (1992) Dopamine denervation leads to an increase in the membrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res 594:124-130.
97. Ferré S and Fuxe K (2000) Adenosine as a volume transmission signal. A feedback detector of neuronal activation, in Progress in Brain Research (Agnati LF, Fuxe K, Nicholson C, and Syková E eds) vol 125, pp 353-361, Elsevier Science B.V., Amsterdam.
98. Ferré S, Fuxe K, von Euler G, Johansson B, and Fredholm BB (1992) Adenosine-dopamine interactions in the brain. Neuroscience 51:501-512.
99. Ferré S, Herrera-Marschitz M, Grabowska-Andén M, Ungerstedt U, Casas M, and Andén N-E (1991a) Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit a D-2 mediated behaviour in short-term reserpinized mice. Eur J Pharmacol 192:25-30.
100. Ferré S, Herrera-Marschitz M, Grabowska-Andén M, Ungerstedt U, Casas M, and Andén N-E (1991b) Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur J Pharmacol 192:31-37.
101. Ferré S, Karcz-Kubícha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, Casado V, Fuxe K, Goldberg SR, Lluis C, et al. (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci USA 99:11940-11945.
102. Ferré S, O'Connor WT, Fuxe K, and Ungerstedt U (1993a) The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 13: 5402-5406.
103. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63:765-773.
104. 1 receptor-mediated mechanisms. Eur J Neurosci 8:1545-1553.
105. Ferré S, Popoli P, Giménez-Llort L, Finnman U-B, Martinez E, Scotti de Carolis A, and Fuxe K (1994b) Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors. Neuroreport 6:73-76.
106. Ferré S, Popoli P, Giménez-Llort L, Rimondini R, Müller CE, Strömberg I, Ögren SO, and Fuxe K (2001) Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat Disord 7:235-241.
107. Ferré S, Popoli P, Rimondini R, Reggio R, Kehr J, and Fuxe K (1999a) Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology 39:129-140.
108. Ferré S, Popoli P, Tinner-Staines B, and Fuxe K (1996b) Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. Neurosci Lett 208:109-112.
109. Ferré S, Rimondini R, Popoli P, Reggio R, Pezzola A, Hansson AC, Andersson A, and Fuxe K (1999b) Stimulation of adenosine A1 receptors attenuates dopamine D1 receptor-mediated increase of NGFI-A, c-fos and jun-B mRNA levels in the dopamine-denervated striatum and dopamine D1 receptor-mediated turning behaviour. Eur J Neurosci 11:3884-3892.
110. 2 receptors induces catalepsy. Neurosci Lett 130:162-164.
111. 2 receptors in rat neostriatal memmbranes. Eur J Pharmacol Mol Pharmacol Sec 244:311-315.
112. Ferré S, Torvinen M, Antoniou K, Irenius E, Civelli O, Arenas, E, Fredholm BB, and Fuxe K (1998) Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. J Biol Chem 273:4718-4724.
113. Ferré S, von Euler G, Johansson B, Fredholm BB, and Fuxe K (1991d) Stimulation of high-affinity adenosine A-2 receptors decreases the affinity of dopamine D-2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 88:7238-7241.
114. 2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14:186-195.
115. Fior D and Fuxe K (1995) Bradykinin modulation of α2-adrenoceptors in the nucleus tractus solitarius of the rat. An in vitro autoradiographical study. Neuropharmacology 34:81-88.
116. Fior D, Yang S-N, Hedlund P, Narvaez JA, Agnati LF, and Fuxe K (1994) α2-adrenoreceptor/angiotensin II receptor interactions in the nucleus tractus solitarius lead to an enhancement of angiotensin II receptor transduction. Pharm Pharmacol Lett 3:237-240.
117. Fior DR, Hedlund PB, and Fuxe K (1993) Autoradiographic evidence for a bradykinin/angiotensin II receptor/receptor interaction in the rat brain. Neurosci Lett 163:58-62.
118. 1 adenosine receptors. Biochemistry 35:3007-3015.
119. Franco R, Casadó V, Ciruela F, Saura C, Mallol J, Canela EI, and Lluis C (1997) Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol (Oxf) 52:283-294.
120. Franco R, Ferré S, Agnati L, Torvinen M, Gines S, Hillion J, Casado V, Lledo PM, Zoli M, Lluis C, et al. (2000) Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 25:S50-S59.
121. Franco R, Ferré S, Torvinen M, Ginés S, Hillion J, Ciruela F, Canela EI, Mallol J, Casadó V, Lluís C, et al. (2001) Adenosine/dopamine receptor/receptor interactions in the central nervous system. Drug Dev Res 52:296-302.
122. Franco R, Mallol J, Casadó V, Lluí C, Canela EI, Saura C, Blanco J, and Ciruela F (1999) Ecto-adenosine deaminase: an ectoenzyme and a costimulatory protein acting on a variety of cell surface receptors. Drug Dev Res 45:261-268.
123. Franco R, Valenzuela A, Lluís C, and Blanco R (1998) Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 161:27-42.
124. Fraser CM and Venter JC (1982) The size of the mammalian lung β2-adrenergic receptor as determined by target size analysis and immunoaffinity chromatography. Biochem Biophys Res Commun 109:21-29.
125. Fraser ID, Cong M, Kim J, Rollins EN, Daaka Y, Lefkowitz RJ, and Scott JD (2000) Assembly of an A kinase-anchoring protein-β2-adrenergic receptor complex facilitates receptor phosphorylation and signaling. Curr Biol 10:409-412.
126. Frauenfelder H, Slígar SG, and Wolynes PG (1991) The energy landscapes and motions of proteins. Science (Wash DC) 254:1598-1603.
127. Fredholm BB (1995a) Purinoceptors in the nervous system. Pharmacol Toxicol 76:228-239.
128. Fredholm BB (1995b) Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 76:93-101.
129. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, and Williams M (1994) Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156.
130. Fredholm BB, Herrera-Marschitz M, Jonzon B, Lindström K, and Ungerstedt U (1983) On the mechanism by which methylxanthines enhance apomorphine induced rotation behaviour in the rat. Pharmacol Biochem Behav 19:535-541.
131. Fredholm BB, Uzerman AP, Jacobson KA, Klotz KN, and Linden J (2001) International union of pharmacology. XXV. Nomenclature and classification of adenosine receptor. Pharmacol Rev 53:527-552.
132. + channels activated by D2 dopamine receptors in acutely dissociated neurons from rat corpus striatum. Proc Natl Acad Sci USA 85:3618-3622.
133. Fuxe K and Agnati LF (1985) Receptor/receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med Res Rev 5:441-482.
134. Fuxe K and Agnati L (1987) Receptor/receptor Interactions. A New Intramembrane Integrative Mechanism, Macmillan, London.
135. Fuxe K, Agnati L, Härfstrand A, Zoli M, von Euler G, Grimaldi R, Merlo Pich E, Bjelke B, Eneroth P, Benfenati F, et al. (1990a) On the role of neuropeptide Y in information handling in the central nervous system in normal and physiopathological states. Ann NY Acad Sci 579:28-67.
136. Fuxe K, Agnati L, Ogren S, Andersson K, and Benfenati F (1983a) Neurobiology of central monoamine neurotransmission: functional neuroanatomy and noradrenaline and 5-hydroxytryptamine involvement in learning and memory, in Neural Transmission, Learning and Memory (Caputto R and Marsan C eds) pp 237-255, Raven Press Ltd., New York.
137. Fuxe K, Agnati LF, Benfenati F, Celani MF, Zini I, Zoli M, and Mutt V (1983b) Evidence for the existence of receptor/receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J Neural Transm 18:165-179.
138. 3H]spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta Physiol Scand 113:567-569.
139. 3H-kainic acid binding sites in rat striatal membranes. Possible relevance for kainic acid neurotoxicity. Neurosci Lett 35:233-238.
140. Fuxe K, Agnati LF, von Euler G, Benfenati F, and Tanganelli S (1990b) Modulation of dopamine D1 and D2 transmission lines in the central nervous system, in Current Aspects of the Neurosciences (Osborne NN ed) pp 203-243, MacMillan, London.
141. Fuxe K, Agnati LF, von Euler G, Benfenati F, Zoli M, Härfstrand A, and Fredholm B (1989) Receptor/receptor interactions and development of psychoactive drugs, in Neurochemical Pharmacology (Costa E ed) pp 211-227, Raven Press Ltd., New York.
142. Fuxe K, Agnati LF, von Euler G, Tanganelli S, O'Connor WT, Ferré S, Hedlund P, and Zoli M (1992a) Neuropeptide, excitatory amino acid and adenosine A2 receptors regulate D2 receptors via intramembrane receptor/ receptor interactions. Relevance for Parkinson's disease and schizophrenia. Neurochem Int 20 (Suppl): 215S-224S.
143. Fuxe K, Aguirre JA, Agnati LF, von Euler G, Hedlund P, Covenas R, Zoli M, Bjelke B, and Eneroth P (1990c) Neuropeptide Y and central cardiovascular regulation. Focus on its role as a cotransmitter in cardiovascular adrenergic neurons. Ann NY Acad Sci 611:111-132.
144. Fuxe K, Celani MF, Martire M, Zini I, Zoli M, and Agnati LF (1984) l-Glutamate reduces the affinity of 3H-N-propylnorapomorphine binding sites in striatal membranes. Eur J Pharmacol 100:127-130.
145. Fuxe K, Ferré S, Snaprud P, von Euler G, Johansson B, and Fredholm B (1993) Antagonistic A2a/D2 receptor interactions in the striatum as a basis for adenosine/ dopamine interactions in the central nervous system. Drug Dev Res 28:374-380.
146. th Int Catecholamine Symposium, Kyoto, Japan; 2001; in press; Kluwer Academic/Plenum Publishers, New York.
147. Fuxe K, Ferré S, Zoli M, and Agnati LF (1998) Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor
148. Fuxe K, Hedlund P, von Euler G, Lundgren K, Martire M, Ögren S, Eneroth P, and Agnati L (1991) Galanin/5-HT interactions in the rat central nervous system. Relevance for depression, in Galanin: A New Multifunctional Peptide in the Neuro-Endocrine System. Wenner-Gren Center International Symposium Series (Hökfelt T, Bartfai T, Jacobowitz D, and Ottoson D eds) vol 58, pp 221-235, MacMillan, London.
149. Fuxe K, Li X-M, Hedlund P, Benfenati F, Agnati L, and Ferré S (1996) Integrative aspects of brain function: receptor/receptor interactions in dopamine transmission of the basal ganglia., in CNS Neurotransmitters and Neuromodulators. Dopamine (Stones TW ed) pp 89-106, CRC Press LLC, Boca Raton, Florida.
150. Fuxe K, Li X-M, Tanganelli S, Hedlund P, O'Connor W, Ferraro L, Ungerstedt U, and Agnati L (1995) Receptor/receptor interactions and their relevance for receptor diversity, in Diversity of Interacting Receptors (Abood L and Lajtha A eds) pp 365-376, New York Academy of Sciences, New York.
151. Fuxe K, O'Connor WT, Antonelli T, Osborne PG, Tanganelli S, Agnati LF, and Ungerstedt U (1992b) Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc Natl Acad Sci USA 89:5591-5595.
152. Fuxe K, Strömberg I, Popoli P, Rimondini-Giorgini R, Torvinen M, Ogren SO, Franco R, Agnati LF, and Ferré S (2001) Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv Neurol 86:345-353.
153. Fuxe K and Ungerstedt U (1974) Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with dopa and dopamine receptor agonists. Med Biol (Helsinki) 52:48-54.
154. Fuxe K, von Euler G, and Agnati L (1988a) Angiotensin II reduces the affinity of 3H-paraaminoclonidine binding sites in membrane preparations from the rat dorsomedial medulla oblongata. Acta Physiol Scand 134:317-318.
155. 3H]nicotine binding by clonidine in membrane preparations of the rat cerebral cortex. Acta Physiol Scand 132:265-266.
156. Fuxe K, von Euler G, Agnati LF, and Ögren SO (1988c) Galanin selectively modulates 5-hydroxytryptamine 1A receptors in the rat ventral limbic cortex. Neurosci Lett 85:163-167.
157. 2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann NY Acad Sci 668:186-204.
158. Fuxe K, von Euler G, Finnman U-B, and Agnati L (1989) Reduction of 3H-nicotine binding in hypothalamic and cortical membranes by dopamine D1 receptors. Acta Physiol Scand 136:295-296.
159. Garrett BE and Holtzman SG (1994) Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction. Eur J Pharmacol 262:65-75.
160. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of μ- and δ-opioid receptors. J Biol Chem 275:26128-26135.
161. George SR, Lee SP, Varghese G, Zeman PR, Seeman P, Ng GY, and O'Dowd BF (1998) A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. J Biol Chem 273:30244-30248.
162. Gerfen CR and Wilson CJ (1996) The basal ganglia, in Handbook of Chem Neuroanatomy (Swanson LW, Björklund A, and Hökfelt T eds) vol 12, part III, pp 371-468, Elsevier Science B.V., Amsterdam.
163. Gether U (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21:90-113.
164. Giménez-Llort L, Martinez E, and Ferré S (1995) Dopamine-independent and adenosine-dependent mechanisms involved in the effects of N-methyl-D-aspartate on motor activity in mice. Eur J Pharmacol 275:171-177.
165. Ginés S, Ciruela F, Burgueño J, Casadó V, Canela EI, Mallol J, Lluís C, and Franco R (2001) Involvement of caveolin in ligand-induced recruitment and internalization of A1 adenosine receptors and adenosine deaminase in an epithelial cell line. Mol Pharmacol 59:1314-1323.
166. Ginés S, Hillion J, Torvinen M, LeCrom S, Casado V, Canela E, Rondin S, Lew J, Watson S, Zoli M, et al. (2000) Dopamine D1 and adenosine A1 receptors assemble into functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97:8606-8611.
167. Goldman-Rakic PS and Selemon LD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437-458.
168. B receptor activity. J Biol Chem 274:7607-7610.
169. Gouldson PR, Higgs C, Smith RE, Dean MK, Gkoutos GV, and Reynolds CA (2000) Dimerization and domain swapping in G-protein-coupled receptors: a computational study. Neuropsychopharmacology 23:60-77.
170. Gouldson PR, Snell CR, Bywater RP, Higgs C, and Reynolds CA (1998) Domain swapping in G-protein coupled receptor dimers. Protein Eng 11:1181-1193.
171. Grant S and Blackstock W (2001) Proteomics in neuroscience: from protein to network. J Neurosci 21:8315-8318.
172. Grant SGN and Husi H (2001) Proteomics of multiprotein complexes: answering fundamental questions in neuroscience. Trends Biotechnol 19:49-54.
173. Greengard P, Allen PB, and Nairn AC (1999) Beyond the dopamine receptor: the DARPP-32/protein pnosphatase-1 cascade. Neuron 23:435-447.
174. Greengard P, Nairn A, Girault JA, Ouimet CC, Snyder GL, Fisone G, Allen PB, Fienberg A, and Nishi A (1998) The DARPP-32/protein phosphate-1 cascade: a model for signal integration. Brain Res Rev 26:274-284.
175. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, and Kase H (1999) Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673-1677.
176. Gurevich EV and Joyce JN (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60-80.
177. Gutkind JS, Coso OA, and Xu N (1998) Gα12 and Gα13-subunits of heterotrimeric G proteins: a novel family of oncogenes, in G proteins, Receptors and Disease (Spiegel AM ed) pp 101-117 Humana Press, Inc., New Jersey.
178. Härfstrand A, Fuxe K, Cintra A, and Agnati L (1988) Aspects on neuropeptide Y/epinephrine cotransmission in central cardiovascular regulation, in Progress in Catecholamine Research. Part B: Central Aspects (Ed?) pp 225-232, Alan R. Liss, New York.
179. Hauber W and Munkle M (1997) Motor depressant effects mediated by dopamine D2 and adenosine A2A receptors in the nucleus accumbens and the caudate-putamen. Eur J Pharmacol 323:127-131.
180. Hauber W, Neuscheler P, Nagel J, and Muller CE (2001) Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur J Neurosci 14:1287-1293.
181. Havlicek V, Rezek M, and Friesen H (1976) Somatostatin and thyrotropin releasing hormone: central effect on sleep and motor system. Pharmacol Biochem Behav 4:455-459.
182. Hebb DO (1949) The organization of behavior; a neuropsychological theory. John Wiley & Sons, New York.
183. 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271:16384-16392.
184. Hedlund P, Finnman U-B, Yanaihara N, and Fuxe K (1994) Galanin-(1-15), but not galanin-(1-29), modulates 5-HT1A receptors in the dorsal hippocampus of the rat brain: possible existence of galanin receptor subtypes. Brain Res 634:163-167.
185. Hedlund P and Fuxe K (1996) Galanin and 5-HT1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain, in Neuropeptides: Basic and Clinical Advances (Crawley J and McLean S eds) pp 193-212, New York Academy of Sciences, New York.
186. 1A receptors increases the affinity of galanin receptors in di- and telencephalic areas of the rat. Brain Res 560:251-259.
187. Heffner TG, Wiley JN, Williams AE, Bruns RE, Coughenour LL, and Downs DA (1989) Comparison of the behavioural effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology 98:31-37.
188. Heimer L, Zahm DS, and Alheid GF (1995) Basal ganglia, in The Rat Nervous System (Paxinos G ed) pp 579-628, Academic Press, Inc., San Diego, CA.
189. Helldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80:213-223.
190. Herberg JT, Codina J, Rich KA, Rojas FJ, and Lyengar R (1984) The hepatic glucagon receptor. Solubilization, characterization and development of an affinity adsorption assay for the soluble receptor. J Biol Chem 259:9285-9294.
191. Herdegen T and Leah JD (1998) Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox and CREB/ATF proteins. Brain Res Rev 28:370-490.
192. Hermans E and Challiss RA (2001) Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem J 359:465-484.
193. Herrera C, Casadó V, Ciruela F, Schofield, P, Mallol J, Llufs C, and Franco R (2001) Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol Pharmacol 59:127-134.
194. Herrera-Marschitz, M, Casas M, and Ungerstedt U (1988) Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses. Psychopharmacology 94:38-45.
195. Hettinger BD, Lee A, Linden J, and Rosin DL (2001) Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431:331-346.
196. Heuss C and Gerber U (2000) G-protein-independent signaling by G-protein-coupled receptors. Trends Neurosci 23:469-475.
197. Hillefors M, Hedlund PB, and von Euler G (1999) Effects of adenosine A(2A) receptor stimulation in vivo on dopamine D3 receptor agonist binding in the rat brain. Biochem Pharmacol 58:1961-1964.
198. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, et al. (2002) Coaggregation, cointernalization and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277:18091-18097.
199. Hollenberg MD (1991) Structure-activity relationship for transmembrane signalling: the receptor's turn, FASEB J 5:178-186.
200. Huganir RL and Greengard P (1987) Regulation of receptor function by protein phosphorylation. Trends Pharmacol Sci 8:472-477.
201. Hughes P and Dragunow M (1995) Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 47:133-178.
202. Hukovic N, Panetta R, Kumar U, Rocheville M, and Patel YC (1998) The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylate cyclase and in mediating desensitization and internalization. J Biol Chem 273:21410-21422.
203. Hunter T (2000) Signalling 2000 and beyond. Cell 100:113-127.
204. A receptor in prefrontal cortex of schizophrenia. Proc Natl Acad Sci USA 95:15066-15071.
205. Husi H and Grant SG (2001) Proteomics of the nervous system. Trends Neurosci 24:259-266.
206. Impey S, Obrietan K, and Storm DR (1999) Making new connections: role of ERK/ MAP kinase signaling in neuronal plasticity. Neuron 23:11-14.
207. Izquierdo-Claros RM, Boyano-Adanez MC, Larsson C, Gustavsson L, and Arilla E (1997) Acute effects of D1- and D2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. Brain Res Mol Brain Res 47:99-107.
208. Jentsch JD and Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
209. Jiang H, Jackson-Lewis V, Muthane U, Dollison A, Ferreira M, Espinosa A, Parsons B, and Przedborski S (1993) Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res 613:347-351.
210. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escoribuela RM, Fernandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, et al. (2001) Hyperalgesia, anxiety and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 98:9407-9412.
211. BR2. Nature (Lond) 396:674-682.
212. Jordan BA, Cvejic S, and Devi LA (2000) Opioids and their complicated receptor complexes. Neuropsychopharmacology 23:S5-S18.
213. Jordan BA and Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature (Lond) 399:697-700.
214. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, and Devi LA (2001) Oligomerization of opioid receptors with β2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 98:343-348.
215. Kafka SH and Corbett R (1996) Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 295: 147-154.
216. B receptor is mediated by parallel coiled-coil α helices. Biochemistry 38:13263-13269.
217. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, and Jenner P (1998a) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513.
218. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, and Jenner P (2000) Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162.321-327.
219. Kanda T, Shiozaki S, Shimada J, Suzuki F, and Nakamura J (1994) KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 256:263-268.
220. Kanda T, Tashiro T, Kuwana Y, and Jenner P (1998b) Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9:2857-2860.
221. Kastin AJ, Coy DH, Jacquet Y, Schally AV, and Plotnikoff NP (1978) CNS effects of somatostatin. Metabolism 27:1247-1252.
222. B-receptor subtypes assemble into functional heteromeric complexes. Nature (Lond) 396:683-687.
223. Kenakin T (1995) Agonist-receptor efficacy. I: mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 16:188-192.
224. Kenakin T (1997) Agonist-specific receptor conformations. TIPS 18:416-417.
225. Keverne EB (1999) GABA-ergic neurons and the neurobiology of schizophrenia and other psychosis. Brain Res Bull 48:467-473.
226. Khakh BS, Zhou X, Sydes J, Galligan JJ, and Lester HA (2000) State-dependent cross-inhibition between transmitter-gated cation channels. Nature (Lond) 406: 405-410.
227. Kieffer BL (1999) Opioids: first lessons from knockout mice. TIPS 20:19-26.
228. Koga K, Kurokawa M, Ochi M, Nakamura J, and Kuwana Y (2000) Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 408:249-255.
229. Kohout TA, Lin FT, Perry SJ, Conner DA, and Lefkowitz RJ (2001) β-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA 98:1601-1606.
230. Koob GF (1999) The role of the striatopallidal and extended amygdala systems in drug addiction. Ann NY Acad Sci 877:445-460.
231. Kozell LB, Machida CA, Neve RL, and Neve KA (1994) Chimeric D1/D2 dopamine receptors. Distinct determinants of selective efficacy, potency and signal transduction. J Biol Chem 269:30299-30306.
232. Kozell LB and Neve KA (1997) Constitutive activity of a chimeric D1/D2 dopamine receptor. Mol Pharmacol 52:1137-1149.
233. Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LEC, and Eidne KA (2001) Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor; detection in living cells using bioluminescence resonance energy transfer. J Biol Chem 276:12736-12743.
234. Kull B, Ferre S, Arslan G, Svenningsson P, Fuxe K, Owman C, and Fredholm BB (1999) Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem Pharmacol 58:1035-1045.
235. Kull B, Svenningsson P, and Fredholm BB (2000) Adenosine A(2A) receptors are colocalized with and activate G(olf) in rat striatum. Mol Pharmacol 58:771-777.
236. B receptor function. Science (Wash DC) 283:74-77.
237. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, and Morikawa K (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (Lond) 407:971-977.
238. 2a receptor-mediated modulation of striatal GABA and Ach release. Br J Pharmacol 113:43-48.
239. Latini S and Pedata F (2001) Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79:463-484.
240. Le F, Groshan K, Zeng XP, and Richelson E (1997) Characterization of the genomic structure, promoter region and a tetranucleotide repeat polymorphism of the human neurotensin receptor gene. J Biol Chem 272:1315-1322.
241. Leblanc R, Gauthier S, Gauvin M, Quirion R, Palmour R, and Masson H (1988) Neurobehavioral effects of intrathecal somatostatinergic treatment in subhuman primates. Neurology 38:1887-1890.
242. Lee SP, Xie Z, Varghese G, Nguyen T, O'Dowd BF, and George SR (2000) Oligomerization of dopamine and serotonin receptors. Neuropsychopharmacology 23:S32-S40.
243. Lefkowitz RJ (2000) The superfamily ofheptahelical receptors. Nat Cell Biol 2:E133-E136.
244. Lemmon MA and Engelman DM (1994) Specificity and promiscuity in membrane helix interactions. FEBS Lett 346:17-20.
245. Lemmon MA, Flanagan JM, Hunt JF, Adair BD, Bormann BJ, Dempsey CE, and Engelman DM (1992) Glycophorin A dimerization is driven by specific interactions between transmembrane alpha-helices. J Biol Chem 267:7683-7689.
246. Le Moine C and Bloch B (1995) D1 and D2 dopamine receptor gene expression in rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 355:418-426.
247. Le Moine C and Bloch B (1996) Expression of the D3 dopamine receptor in peptideric neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. Neuroscience 73:131-143.
248. Lepiku M, Rinken A, Jarv J, and Fuxe K (1997) Modulation of [3H]quinpirole binding to dopaminergic receptors by adenosine A2A receptors. Neurosci Lett 239:61-64.
249. Levac BA, O'Dowd BF, and George SR (2002) Oligomerization of opioid receptors: generation of novel signaling units. Curr Opin Pharmacol 2:76-81.
250. Lezcano N, Mrzljak L, Eubanks S, Levenson R, Goldman-Rakic P, and Bergson C (2000) Dual signaling regulated by Calcyon, a D1 dopamine receptor interacting protein. Science (Wash DC) 287:1660-1664.
251. Li XM, Ferraro L, Tanganelli S, O'Connor W, Hasselrot U, Ungerstedt U, and Fuxe K (1995a) Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study. J Neural Transm 102:125-137.
252. 2 receptor agonist binding in the rat neostriatum. Neurosci Lett 155:121-124.
253. Li XM, Hedlund P, Agnati LF, and Fuxe K (1994a) Dopamine D1 receptors are involved in the modulation of D2 receptors induced by cholecystokinin receptor subtypes in rat neostriatal membranes. Brain Res 650:289-298.
254. Li X-M, Hedlund P, and Fuxe K (1994b) Strong effects of NT/NN peptides on DA D2 receptors in rat neostriatal sections. Neuroreport 5:1621-1624.
255. Li XM, Hedlund PB, and Fuxe K (1995b) Cholecystokinin octapeptide in vitro and ex vivo strongly modulares striatal dopamine D2 receptors in rat forebrain sections. Eur J Neurosci 7:962-971.
256. 2 receptors. Eur J Pharmacol 234:125-128.
257. Lillrank SM, Lipska BK, Weinberger DR, Fredholm BB, Fuxe K, and Ferré S (1999) Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Neurochem Int 34:235-244.
258. Limbird LE and Lefkowitz RJ (1976) Negative cooperativity among β-adrenergic receptors in frog erythrocyte membranes. J Biol Chem 251:5007-5014.
259. Limbird LE, Mayts PD, and Lefkowitz RJ (1975) Beta-adrenergic receptors: evidence for negative cooperativity. Biochem Biophys Res Commun 64:1160-1168.
260. Lindskog M, Svenningsson P, Fredholm BB, Greengard P, and Fisone G (1999) Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience 88:1005-1008.
261. Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, Fredholm BB, Nairn AC, Greengard P, and Fisone G (2002) Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature (Lond) 418:774-778.
262. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, and Niznik HB (2000) Direct protein-protein coupling enables cross-talk between dopamine D5 and γ-aminobutyric acid A receptors. Nature (Lond) 403:274-280.
263. Lluis C, Cordero O, and Franco R (1998) Ecto-adenosine deaminase may play a relevant role in the development of the immune syste. Immunol Today 19:533-534.
264. Lundberg JM, Hedlund B, and Bartfai T (1982) Vasoactive intestinal polypeptide enhances muscarinic ligand binding in cat submandibular salivary gland. Nature (Lond) 295:147-149.
265. 2 adrenergic receptor-Src protein kinase complexes. Science (Wash DC) 283:655-661.
266. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, and Lefkowitz RJ (2001) Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc Natl Acad Sci USA 98:2449-2454.
267. Maggi A, U'Prichard DC, and Enna SJ (1980) Beta-adrenergic regulation of alpha 2-adrenergic receptors in the central nervous system. Science (Wash DC) 207:645-647.
268. Maggio R, Vogel Z, and Wess J (1993) Coexpression studies with mutant muscarinic/ adrenergic receptors provide evidence for intermolecular 'cross-talk' between G-protein-linked receptors. Proc Natl Acad Sci USA 90:3103-3107.
269. Malec D (1997) Haloperidol-induced catalepsy is infiuenced by adenosine receptor antagonists. Pol J Pharmacol Pharm 49:323-327.
270. Manzoni O, Pujalte D, Williams J, and Bockaert J (1998) Decreased presynaptic sensitivity to adenosine after cocaine withdrawal. J Neurosci 18:7996-8002.
271. Margeta-Mitrovic M, Jan YN, and Jan LY (2000) A trafficking checkpoint controls GABAB receptor heterodimerization. Neuron 27:97-106.
272. Marinissen MJ and Gurkind JS (2001) G-protein-coupled receptors and signaling networks:emerging paradigms. Trends Pharmacol Sci 22:368-376.
273. Marshall FH (2001) Heterodimerization of G protein coupled receptors in the CNS. Curr Opin Pharmacol 1:40-44.
274. Marshall FH, Jones KA, Kaupmann K, and Bettler B (1999) GABAA receptors -the first 7TM heterodimers. Trends Pharmacol Sci 10:369-399.
275. Martin-Iverson MT, Radke JM, and Vincent SR (1986) The effects of cysteamine on dopamine-mediated behaviors: evidence for dopamine-somatostatin interactions in the striatum. Pharmacol Biochem Behav 24:1707-1714.
276. 2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275:9572-9580.
277. 2 receptor interaction in globus pallidus. Synapse 22:132-138.
278. Mayfield RD, Jones BA, Miller HA, Simosky JK, Larson GA, and Zahniser NR (1999) Modulation of endogenous GABA release by an antagonistic adenosine A1/dopamineD1 receptor interaction in rat brain limbic regions but not basal ganglia. Synapse 33:274-281.
279. Mayr B and Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev 2:599-609.
280. McDonald PH and Lefkowitz RJ (2001) βArrestins: new roles in regulating hepta-helical receptors' functions. Cell Signal 13:683-689.
281. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, and Foord SM (1998) Ramps regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature (Lond) 393:333-339.
282. McVey M, Ramsay D, Kellett E, Rees S, Wilson S, Pope AJ, and Milligan G (2001) Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. J Biol Chem 276:14092-14099.
283. Mendoza-Fernandez V, Andrew RD, and Barajas-López C (2000) ATP inhibits glutamate synaptic release by acting at P2Y receptors in pyramidal neurons of hippocampus slices. J Pharmacol Exp Ther 293:172-179.
284. Merchant KM and Dorsa DM (1993) Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci USA 90:3447-3451.
285. Migaud M, Charlesworth P, Dempster M, Webster LC, Watabe AM, Makhinson M, He Y, Ramsay MF, Morris RG, Morrison JH, et al. (1998) Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature (Lond) 396:433-439.
286. Miller WE and Lefkowitz RJ (2001) Expanding roles for β-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr Opin Cell Biol 13:139-145.
287. Milligan G and White JH (2001) Protein-protein interactions at G-protein-coupled receptors. Trends Pharmacol Sci 22:513-518.
288. Mirabet M, Herrera C, Cordero OJ, Mallol J, Lluis C, and Franco R (1999) Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci 112:491-502.
289. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
290. B receptor heterodimerization. Neuron 27:97-106.
291. Monnot C, Bihroreau C, Conchou S, Curnow KM, Corvol P, and Clauser E (1996) Polar residues in the transmembrane domain of the type I angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by coexpression of two deficient mutants. J Biol Chem 271:1507-1513.
292. Morelli M, Pinna A, Wardas J, and Di Chiara G (1995) Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience 67:49-55.
293. Morelli M and Wardas J (2001) Adenosine A2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotox Res 3:545-556.
294. 2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 15:605-611.
295. Mrzljak L, Levey AI, and Goldman-Rakic PS (1993) Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 90:5194-5198.
296. Naisbitt S, Kim E, Tu J, Xiao B, Sala C, Valtschanoff J, Weinberg R, Worley P, and Sheng M (1999) Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23:569-582.
297. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, and Coughlin SR (2000) PAR3 is a cofactor for PAR4 activation by thrombin. Nature (Lond) 404:609-613.
298. Nemeroff CB (1986) The interactions of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology 11:15-37.
299. Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, et al. (2001) Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol 59:144-152.
300. Ng GY, Clark J, Coulombe N, Ethier N, Hebert TE, Sullivan R, Kargman S, Chateauneuf A, Tsukamoto N, McDonald T, et al. (1999) Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J Biol Chem 274:7607-7610.
301. Ng GY, George SR, Zastawny RL, Caron M, Bouvier M, Dennis M, and O'Dowd BF (1993) Human serotonin1B receptor expression in Sf9 cells: phospholylation, palmitoylation and adenylyl cyclase inhibition. Biochemistry 32:11727-11733.
302. Ng GY, Mouillac B, George SR, Caron M, Dennis M, Bouvier M, and O'Dowd BF (1994a) Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor. Eur J Pharmacol 267:7-19.
303. Ng GY, O'Dowd BF, Caron M, Dennis M, Brann MR, and George SR (1994b) Phosphorylation and palmitoylation of the human D2L dopamine receptor in Sf9 cells. J Neurochem 63:1589-1595.
304. Ng GY, O'Dowd BF, Lee SP, Chung HT, Brann MR, Seeman P, and George SR (1996) Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 227:200-204.
305. Nguyen JT, Turck CW, Cohen FE, Zuckermann RN, and Lim WA (1998) Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors. Science (Wash DC) 282:2088-2092.
306. Nimchinsky EA, Hof PR, Janssen WG, Morrison JH, and Schmauss C (1997) Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J Biol Chem 272:29229-29237.
307. Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, and Greengard P (2002) Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci USA 97:12840-12845.
308. A receptor in relation to specific GABAergic synapses in the dentate gyrus. Eur J Neurosci 7:630-636.
309. Obeso JA, Rodriguez-Oroz C, Rodriguez M, Macias R, Alvarez L, Guridi J, Vitek J, and DeLong MR (2000) Pathophysiologic basis of surgery for Parkinson's disease. Neurology 55:S7-S12.
310. Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, and Kuwana Y (2000) Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 100:53-62.
311. Ogren SO (1996) The behavioural pharmacology of typical and atypical antipsychotic drugs, in Handbook of experimental Pharmacology (Csernansky JG ed) vol 120, pp 225-265, Springer-Verlag, Berlin, Germany.
312. Ogren SO and Goldstein M (1994) Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11:167-177.
313. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, et al. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature (Lond) 385:634-636.
314. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, and Pilc A (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41:413-420.
315. a. J Pharmacol Exp Ther 294:407-412.
316. Overton MC and Blumer KJ (2000) G protein coupled receptors function as oligomers in vivo. Curr Biol 10:341-344.
317. Paolillo M, Montecucco A, Zanassi P, and Schinelli S (1998) Potentiation of dopamine-induced cAMP formation by group I metabotropic glutamate receptors via protein kinase C in cultured striatal neurons. Eur J Neurosci 10:1937-1945
318. Pawson T (1995) Protein modules and signalling networks. Nature (Lond) 373:573-580.
319. Pawson T, Gish G, and Nash P (2001) SH2 domains, interaction modules and cellular wiring. Trends Cell Biol 11:504-511.
320. Pawson T and Scott JD (1997) Signaling through scaffold, anchoring and adaptor proteins. Science (Wash DC) 278:2075-2080.
321. Pérez de la Mora M, Ferré S, and Faxe K (1997) GABA-dopamine receptor/receptor interactions in neostriatal membranes of the rat. Neurochem Res 22:1051-1054.
322. Perry KJ, Quiza M, Myers DE, Morfis M, Christopoulos G, and Sexton PM (1997) Characterization of amylin and calcitonin receptor binding in the mouse alpha-thyroid-stimulating hormone thyrotroph cell line. Endocrinology 138:3486-3496.
323. Peterson GL, Rosenbaum LC, Brederick DJ, and Schimerlick MI (1986) Physical properties of the purified cardiac muscarinic acetylcholine receptor. Biochemistry 25:3189-3202.
324. Pierce KL and Lefkowitz RJ (2001) Classical and new roles of β-arrestins in the regulation of G-protein-coupled receptors. Neuroscience 2:727-733.
325. Pin JP and Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1-26.
326. Pinna A, Fenu S, and Morelli M (2001) Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39:233-238.
327. Pinna A, Wardas J, Cozzolino A, and Morelli M (1999) Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. Neuropsychopharmacology 20:44-51.
328. Pinna A, Wardas J, Cristalli G, and Morelli M (1997) Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas. Brain Res 759: 41-49.
329. Phonphok Y and Rosenthal KS (1991) Stabilization of clathrin vesicles by amantadine, tromantadine and other hydrophobic amines. FEBS Lett 281:188-190.
330. Poleszak E and Malec D (2000) Influence of adenosine receptor agonists and antagonists on amphetamine-induced stereotypy in rats. Pol J Pharmacol Pharm 52: 423-429.
331. Pollack AE and Fink JS (1995) Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68:721-728.
332. Popoli P, Caporali MG, and Scotti de Carolis A (1991) Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility. J Pharm Pharmacol 43:280-281.
333. Popoli P, Pezzola A, and Scotti de Carolis AS (1994) Modulation of striatal adenosine A1 and A2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. Eur J Pharmacol 257:21-25.
334. Popoli P, Pezzola A, Torvinen M, Reggio R, Pintor A, Scarchilli L, Fuxe K, and Ferré S (2001) The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 25:505-513.
335. Popoli P, Reggio R, and Pezzola A (2000) Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake. Neuropsychopharmacology 22:522-529.
336. Quijano VJ Jr and Sheffield LG (1998) Prolactin decreases epidermal growth factor receptor kinase activity via a phosphorylation-dependent mechanism. J Biol Chem 273:1200-1207.
337. Richardson PJ, Kase H, and Jenner (1997) Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 18: 338-344.
338. Rimondini R, Ferre S, Ogren SO, and Fuxe K (1997) Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17:82-91.
339. Rimondini R, Ferre S, Gimenez-Llort L, Ogren SO, and Fuxe K (1998) Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur J Pharmacol 347:153-158.
340. Rimondini R, Fuxe K and Ferré S (1999) Multiple intramembrane receptor/receptor interactions in the regulation of striatal dopamine D2 receptors. Neuroreport 10:2051-2054.
341. Robertson GS and Fibiger HC (1992): Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328.
342. 2 dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain. Neuroscience 64:1019-1034.
343. Robinsson SW and Caron MG (1997) Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol PharmacoI 52:508-514.
344. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, and Patel YC (2000a) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science (Wash DC) 288:154-157.
345. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, and Patel YC (2000b) Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-7869.
346. Rodriguez-Sanchez MN, Puebla L, Lopez-Samudo S, Rodriguez-Martin E, Marti-Espinosa A, Rodriguez-Pena MS, Juarranz MG, and Arilla E (1997) Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus. J Neurosci Res 47:238-248.
347. Romano C, Yang WL, and O'Malley KL (1996) Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem 271:28612-28616.
348. Rosin DL, Robeva A, Woodard RL, Guyenet PG, and Linden J (1998) Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 401:163-186.
349. Rostene WH, Fischette CT, and McEwen BS (1983a) Modulation by VIP of serotonin receptors in membranes from rat hippocampus. J Neurosci 3:2414-2419.
350. Rostene WH, Fischette CT, Rainbow TC, and McEwen BS (1983b) Modulation by VIP of serotonin receptors in the dorsal hippocampus of the rat brain: an autoradiographic study. Neurosci Lett 37:143-148.
351. Rothmann RB, Long JB, Bykov V, Jacobson AE, Rice KC, and Holaday JW (1988) Beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J Pharmacol Exp Ther 247:405-416.
352. Ruiz MA, Escriche M, Lluis C, Franco R, Martin M, Andres A, and Ros M (2000) Adenosine A1 receptor in cultured neurons from reat cerebral cortex: colocalization with adenosine, deaminase. J Neurochem 75:656-664.
353. Salim H, Ferré S, Dalal A, Peterfreund RA, Fuxe K, Vincent JD, and Lledo PM (2000) Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells. J Neurochem 74:432-439.
354. Sarrió S, Casadó V, Escriche M, Ciruela F, Mallol J, Canela EI, Lluís C, and Franco R (2000) The heat shock cognate protein hsc73 assembles with A1 adenosine receptors to form functional modules in the cell membrane. Mol Cell Biol 20:5164-5174.
355. 1 adenosine receptors in pig brain cortical membranes. J Neurochem 66:1675-1682.
356. 1 adenosine receptors internalize together following agonist-induced receptor desensitization. J Biol Chem 27:17610-17617.
357. 3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 276:30308-30314
358. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57:1062-1067.
359. Schiffmann SN and Vanderhaeghen JJ (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 13:1080-1087.
360. Schlessinger J (1988) Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci 13:443-447.
361. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225.
362. 125I]beta-endorphin to opioid receptors in rat striatal membrane: biochemical evidence for the existence of a mu/delta opioid receptor complex. J Pharmacol Exp Ther 253:419-426.
363. Schulte G and Fredholm BB (2000) Human adenosine A(1), A(2A), A(2B) and A(3) receptors expressed in Chinese hamster ovary cells mediate the phosphorylation of extracellular-regulated kinase. Mol Pharmacol 58:477-482.
364. Schulz A, Grosse R, Schultz G, Gudermann T, and Schoneberg T (2000) Structural implications for receptor oligomerization from functional reconstitution studies of mutant V2 vasopressin receptors. J Biol Chem 275:2381-2389.
365. Seeman P, Niznik HB, Guan HC, Booth G, and Ulpian C (1989) Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA, 86:10156-10160.
366. Sheng M and Kim E (2000) The Shank family of scaffold proteins. J Cell Sci 113:1851-1856.
367. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, and Mizuno N (1993) Immunohistochemical localization ofa metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 163:53-57.
368. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, and Kuwana Y (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147:90-95.
369. Sills TL, Azampanah A, and Fletcher PJ (2001) The adenosine A2A agonist CGS 21680 reverses the reduction in prepulse inhibition of the acoustic startle response induced by phencyclidine, but not by apomorphine and amphetamine. Psychopharmacology 156:187-193.
370. Smith Y, Charara A, Hanson JE, Paquet M, and Levey AI (2000) GABA(B) and group I metabotropic glutamate receptors in the striatopallidal complex in primates. J Anat 196:555-576.
371. 2 receptor interactions are not observed in COS-7 cells transiently transfected with dopamine and adenosine A2A receptor cDNA. Biochem Pharmacol 48:2043-2047.
372. Snyder SH (1985) Adenosine as a neuromodulator. Ann Rev Neurosci 8:103-124.
373. Strömberg I, Popoli P, Muller CE, Ferré S, and Fuxe K (2000) Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci 12:4033-4037.
374. Sung KW, Choi S, and Lovinger DM (2001) Activation ofgroup I mGluRs is necessary for induction of long-term depression at striatal synapses. J Neurophysiol 86:2405-2412.
375. Svenningsson P, Fourreau L, Bloch B, Fredholm BB, Gonon F, and Le Moine C (1999a) Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons. Neuroscience 89:827-837.
376. Svenningsson P, Le Moine C, Fisone G, and Fredholm BB (1999b) Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol (Oxford) 59:355-396.
377. Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, and Fredholm BB (1997) Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 80:1171-1185.
378. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, and Fisone G (2000) Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1 dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA 97:1856-1860.
379. Svenningsson P, Lindskog M, Rognoni F, Fredholm BB, Greengard P, and Fisone G (1998) Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84:223-228.
380. Sweatt JD (2001) The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76:1-10.
381. Tallaksen-Greene SJ, Kaatz KW, Romano C, and Albin RL (1998) Localization of mGluR1α-like immunoreactiv¡ty and mGlur5-like immunoreactivity in identified populations of striatal neurons. Brain Res 780:210-217.
382. Tallman J (2000) Dimerization of G-protein-coupled receptors: implications for drug design and signaling. Neuropsychopharmacology 23:S1-S2.
383. Tanganelli S, Fuxe K, Antonelli T, O'Connor WT, and Ferraro L (2001) Cholecystokinin/dopamine/GABA interactions in the nucleus accumbens: biochemical and functional correlates. Peptides 22:1229-1234.
384. Tanganelli S, Fuxe K, von Euler G, Agnati LF, Ferraro L, and Ungerstedt U (1990) Involvement of cholecystokinin in the control of striatal dopamine autoreceptors. Naunyn-Schmiedeberg's Arch Pharmacol 342:300-304.
385. Tanganelli S, Li X-M, Ferraro L, von Euler G, O'Connor WT, Bianchi C, Beani L, and Fuxe K (1993) Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. Eur J Pharmacol 230:159-166.
386. Tanganelli S, von Euler G, Fuxe K, Agnati LF, and Ungerstedt U (1989) Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum. Brain Res 502:319-324.
387. Testa CM, Standaert DG, Landwehrmeyer GB, Penney JB, and Young AB (1995) Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. J Comp Neurol 354:241-252.
388. Testa CM, Standaert DG, Young AB, and Penney JB (1994) Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 14:3005-3018.
389. 1 receptors in stably cotransfected fibroblast cells and neurons. Neuroscience 113:709-719.
390. Torvinen M, Liu Y, Kozell LB, Neve KA, Ferré S, Ibañez C, and Fuxe K (2001) Dopamine D2 receptor domains involved in the intramembrane interaction between adenosine A2A and dopamine D2 receptors. Soc Neurosci Abstr 27:379.3.
391. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan A, Aakalu WK, Lanahan AA, Sheng M, et al. (1999) Coupling of mGluR/Homer and PSD-95 complexes by the shank family of postsynaptic density proteins. Neuron 23:583-592.
392. Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, Linden DJ, and Worley PF (1998) Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron 21:717-726.
393. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69-93.
394. Uslaner J, Badiani A, Norton CS, Day HE, Watson SJ, Akil H, and Robinson TE (2001) Amphetamine and cocaine induce different patterns of c-fos mRNA expression in the striatum and subthalamic nucleus depending on environmental context. Eur J Neurosci 13:1977-1983.
395. Vanhoutte P, Barnier JV, Guibert B, Pages C, Besson MJ, Hipskind RA, and Caboche J (1999) Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated kinase-dependent pathway in brain slices. Mol Cell Biol 19:136-146.
396. Venter JC and Fraser CM (1983) Beta-adrenergic receptor isolation and characterization with immobilized drugs and monoclonal antibodies. Fed Proc 42:273-278.
397. von Euler G (1991) Biochemical characterization of the intramembrane interaction between neurotensin and dopamine D2 receptors in the rat brain. Brain Res 561:93-99.
398. von Euler G and Fuxe K (1987) Neurotensin reduces the affinity of D2 dopamine receptors in rat striatal membranes. Acta Physiol Scand 131:525-526.
399. 2-adrenoceptors. Eur J Pharmacol 172:435-441.
400. von Euler G, van der Ploeg I, Fredholm BB, and Fuxe K (1991) Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism. J Neurochem 56:178-183.
401. Wang JQ and McGinty JF (1997) The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. J Pharmacol Exp Ther 281:972-982.
402. Wang YT (2002) Dopamine D5/GABA-A heteromerization - a mechanism to regulate synaptic weight. Collegium Internationale Neuro-Psychopharmacologicum 2002, June 23-27; Abstract, ref nr: 901, Animula Publishing House, Budapest, Hungary.
403. Ward RP and Dorsa DM (1999) Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration. Neuroscience 89:927-938.
404. Wardas J, Konieczny J, and Lorenc-Koci E (2001) SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41:160-171.
405. Weng G, Bhalla US, and Iyengar R (1999) Complexity in biological signalling systems. Science (Wash DC) 284:92-96.
406. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM, and Marshall FH (1998) Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature (Lond) 396:679-682.
407. Williams, GV and Goldman-Rakic PS (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature (Lond) 376:572-575.
408. Wirkner K, Assmann H, Koles L, Gerevich Z, Franke H, Norenberg W, Boehm R, and Illes P (2000) Inhibition by adenosine A(2A) receptors of NMDA but not AMPA currents in rat neostriatal neurons. Br J Pharmacol 130:259-269.
409. Wrighton NC, Farrell FX, Chang R, Kashvap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, and Dower WJ (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science (Wash DC) 273:458-463.
410. Wu GY, Deisseroth K, and Tsien RW (2001) Activity-dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 98:2808-2813.
411. Xiao B, Tu JC, and Worley PF (2000) Homer: a link between neural activity and glutamate receptor function. Curr Opin Neurobiol 10:370-374.
412. 1D receptors from homodimers when expressed alone and heterodimers when coexpressed. FEBS Lett 456:63-67.
413. Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, Wada M, Honjo M, Takahashi M, Takahashi T, and Hirai T (1997) Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature (Lond) 390:91-96.
414. Yan Z, Feng J, Fienberg AA, and Greengard P (1999) D2 dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc Natl Acad Sci USA 96:11607-11612.
415. 2 (long-form) receptor co-transfected mouse fibroblast cell lines: studies on intracellular calcium levels. Neuroscience 68:729-736.
416. Yang S-N, Finnman U-B, and Fuxe K (1996) The non-peptide neuropeptide Y Y1 receptor antagonist BIBP3226 blocks the [Leu31,Pro34]neuropeptide Y-induced modulation of a2-adrenoceptors in the nucleus tractus solitarii of the rat. Neuroreport 7:2701-2705.
417. Yang S-N, Fior D, Hedlund P, Agnati LF, and Fuxe K (1994a) Selective modulation of the NPY receptors of the Y2 subtype by a2 receptors in the nucleus tractus solitarii of the rat. A cardiovascular and quantitative receptor autoradiographical analysis. Brain Res 654:137-144.
418. Yang S-N, Fior D, Hedlund PB, Agnati LF, and Fuxe K (1994b) Antagonistic egulation of α2-adrenoceptors by neuropeptide Y receptor subtypes in the nucleus tractus, solitarii. Eur J Pharmacol 271:201-212.
419. Yoshioka K, Saitoh O, and Nakata H (2001) Heteromeric association creates a P2Y-like adenosine receptor. Proc Natl Acad Sci USA 98:7617-7622.
420. Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, and Levey AI (1995) Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65:709-730.
421. Zahniser NR, Simosky JK, Mayfield RD, Negri CA, Hanania T, Larson GA, Kelly MA, Grandy DK, Rubinstein M, Low MJ, et al. (2000) Functional uncoupling of adenosine A(2A) receptors and reduced response to caffeine in mice lacking dopamine D2 receptors. J Neurosci 20:5949-5957.
422. Zarbin MA, Wamsley JK, and Kuhar MJ (1982) Axonal tansport of muscarinic cholinergic receptors in rat vagus nerve: high and low affinity agonist receptors move in opposite directions and differ in nucleotide sensitivity. J Neurosci 2:934-941.
423. Zawarynski P, Tallerico T, Seeman P, Lee SP, O'Dowd BF, and George SR (1998) Dopamine D2 receptor dimers in human and rat brain. FEBS Lett 441:383-386.
424. Zeng EY, Pearce RK, MacKenzie GM, and Jenner P (2000) Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12:1096-1104.
425. Zoli M, Agnati LF, Hedlund PB, Li XM, Ferré S, and Fuxe K (1993) Receptor/receptor interactions as an integrative mechanism in nerve cells. Mol Neurobiol 7:293-334.
426. Zoli M, Guidolin D, Fuxe K, and Agnati L (1996) The receptor mosaic hypothesis of the engram: possible relevance of Boolean network modeling. Int J Neural Syst 7:363-368.